Consequently, further in‐depth research on GPR37 will not only help reveal the development mechanism and tumor drug resistance mechanism of NSCLC but also use GPCR as a drug target to provide a theoretical basis for individualized treatment options for NSCLC. The gene discussed is GPR37; the disease is neoplasm.